Intravenous alteplase for stroke with unknown time of onset guided by advanced imaging: systematic review and meta-analysis of individual patient data.

Link: https://doi.org/S0140-6736(20)32163-2
Authors: Thomalla, Götz; Boutitie, Florent; Ma, Henry; Koga, Masatoshi; Ringleb, Peter; Schwamm, Lee H; Wu, Ona; Bendszus, Martin; Bladin, Christopher F; Campbell, Bruce C V; Cheng, Bastian; Churilov, Leonid; Ebinger, Martin; Endres, Matthias; Fiebach, Jochen B; Fukuda-Doi, Mayumi; Inoue, Manabu; Kleinig, Timothy J; Latour, Lawrence L; Lemmens, Robin; Levi, Christopher R; Leys, Didier; Miwa, Kaori; Molina, Carlos A; Muir, Keith W; Nighoghossian, Norbert; Parsons, Mark W; Pedraza, Salvador; Schellinger, Peter D; Schwab, Stefan; Simonsen, Claus Z; Song, Shlee S; Thijs, Vincent; Toni, Danilo; Hsu, Chung Y; Wahlgren, Nils; Yamamoto, Haruko; Yassi, Nawaf; Yoshimura, Sohei; Warach, Steven; Hacke, Werner; Toyoda, Kazunori; Donnan, Geoffrey A; Davis, Stephen M; Gerloff, Christian; ,

Abstract: Patients who have had a stroke with unknown time of onset have been previously excluded from thrombolysis. We aimed to establish whether intravenous alteplase is safe and effective in such patients when salvageable tissue has been identified with imaging biomarkers. We did a systematic review and meta-analysis of individual patient data for trials published before Sept 21, 2020. Randomised trials of intravenous alteplase versus standard of care or placebo in adults with stroke with unknown time of onset with perfusion-diffusion MRI, perfusion CT, or MRI with diffusion weighted imaging-fluid attenuated inversion recovery (DWI-FLAIR) mismatch were eligible. The primary outcome was favourable functional outcome (score of 0-1 on the modified Rankin Scale [mRS]) at 90 days indicating no disability using an unconditional mixed-effect logistic-regression model fitted to estimate the treatment effect. Secondary outcomes were mRS shift towards a better functional outcome and independent outcome (mRS 0-2) at 90 days. Safety outcomes included death, severe disability or death (mRS score 4-6), and symptomatic intracranial haemorrhage. This study is registered with PROSPERO, CRD42020166903. In patients who have had a stroke with unknown time of onset with a DWI-FLAIR or perfusion mismatch, intravenous alteplase resulted in better functional outcome at 90 days than placebo or standard care. A net benefit was observed for all functional outcomes despite an increased risk of symptomatic intracranial haemorrhage. Although there were more deaths with alteplase than placebo, there were fewer cases of severe disability or death. None.